The U.S. Food and Drug Administration has approved an investigational new drug application for AK0406, a long-acting antiviral compound structured as a drug-Fc conjugate developed by Shanghai Ark Biopharmaceutical (ArkBio), clearing the path toward a Phase II trial aimed at influenza prevention among the general population in the United States.
Annual flu vaccination sits at the centre of public health efforts to contain influenza. Shifts in circulating strains, combined with variation in individual immune responses, can reduce vaccine effectiveness — an effect that tends to be more pronounced in older adults and those with compromised immunity. Broadening the range of available preventive strategies would address needs that current options leave unmet.
Data from the U.S. Centers for Disease Control and Prevention for the 2025–2026 flu season recorded approximately 32 million illnesses, around 380,000 hospitalisations, and roughly 24,000 deaths across the country — outcomes that occurred with flu vaccines available.
AK0406, developed and brought to the research pipeline by ArkBio, represents a compound targeting AFC pathways that had not previously existed in the field. Engineered with several potent antiviral compounds attached at precise positions along an antibody Fc domain, AK0406 draws on two distinct mechanisms — direct antiviral action and Fc-driven immune clearance — to guard against influenza, with potential for broader therapeutic application.
Early-stage laboratory testing of AK0406 demonstrated activity against a wide range of influenza A and B strains with considerable potency. Adjustments to the compound's pharmacokinetic profile and the manufacturing process for GMP compliance were also carried out during development.
An Australian Human Research Ethics Committee granted clearance for AK0406 to enter a Phase I clinical trial in February 2026. Recruitment and initial dosing across every cohort concluded under ArkBio's management that July 2026, at which point the trial moved into its follow-up monitoring stage. China's National Medical Products Administration granted regulatory clearance for an investigational new drug application covering AK0406 in August 2026.
The FDA's regulatory clearance represents a further step in AK0406's international clinical programme. The planned U.S. Phase II trial will be a randomised, double-blind, placebo-controlled study enrolling adult participants across multiple sites over an influenza season. The trial's central aim is to assess whether AK0406 can protect against influenza.
Researchers will also use the trial to examine tolerability, pharmacokinetics, immune response, and any adverse effects associated with the treatment. Findings from that dataset are expected to inform how AK0406 is positioned for expansion across international markets.
Regulatory engagement with both the FDA and China's NMPA drug-evaluation body is set to continue as ArkBio advances its Phase II programme across the two markets. The company is running parallel development tracks, positioning AK0406 as an additional tool in influenza prevention — one intended to address viral mutation and the gaps vaccines leave, particularly for individuals whose health makes them more vulnerable to serious illness.
ArkBio operates as a biopharmaceutical company focused on bringing new treatments to patients with respiratory, lung, and paediatric conditions, and has moved beyond early research into active commercialisation of its therapeutic pipeline. Founded a decade ago, the firm has built proprietary technology platforms alongside a research and development pipeline developed through both in-house work and external partnerships.
Among the compounds advancing through the pipeline, ziresovir (AK0529) is a direct-acting antiviral targeting RSV that has cleared Phase III testing with positive outcomes; AK3280 is an anti-fibrotic candidate for idiopathic pulmonary fibrosis that posted positive Phase II data and has since advanced into a Phase III trial; and AK0901 has received regulatory approval in China and entered commercial use for ADHD. ArkBio's external network includes collaborations with global and domestic pharmaceutical companies — among them Roche, Genentech, and Qilu Pharmaceutical — as well as research institutions including The Scripps Research Institute and the Institute of Microbiology at the Chinese Academy of Sciences.
